Daxor Corporation

13.70-0.2093-1.50%Vol 1.80K1Y Perf 46.26%
Aug 11th, 2022 15:59 DELAYED
BID13.10 ASK17.73
Open13.84 Previous Close13.91
Pre-Market- After-Market-
 - -  - -%
Target Price
22.00 
Analyst Rating
Strong Buy 1.00
Potential %
60.58 
Finscreener Ranking
★★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+ —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
86.68 
Earnings Rating
Buy
Market Cap55.35M 
Earnings Date
28th Mar 2012
Alpha0.05 Standard Deviation0.28
Beta-1.00 

Today's Price Range

13.6214.00

52W Range

8.8214.45

5 Year PE Ratio Range

-98.1027.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.44%
1 Month
9.60%
3 Months
5.88%
6 Months
24.43%
1 Year
46.26%
3 Years
51.38%
5 Years
126.07%
10 Years
56.89%

TickerPriceChg.Chg.%
DXR13.70-0.2093-1.50
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
90.72
RevenueValueIndustryS&P 500US Markets
6.94M
1.72
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2011--0.35-
Q03 2011--0.99-
Q02 2011--0.04-
Q01 2011--0.31-
Q04 2010-0.53-
Q03 2010-0.62-
Q02 2010-0.04-
Q01 2010--0.02-
Earnings Per EndEstimateRevision %Trend
12/2007 QR---
3/2008 QR---
12/2020 FY0.150.00-
12/2021 FY0.400.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.80K
Shares Outstanding4.04K
Shares Float1.29M
Trades Count48
Dollar Volume24.83K
Avg. Volume2.52K
Avg. Weekly Volume1.83K
Avg. Monthly Volume3.47K
Avg. Quarterly Volume2.27K

Daxor Corporation (AMEX: DXR) stock closed at 13.7 per share at the end of the most recent trading day (a -1.5% change compared to the prior day closing price) with a volume of 1.80K shares and market capitalization of 55.35M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 750 people. Daxor Corporation CEO is Michael Feldschuh.

The one-year performance of Daxor Corporation stock is 46.26%, while year-to-date (YTD) performance is 21.35%. DXR stock has a five-year performance of 126.07%. Its 52-week range is between 8.82 and 14.45, which gives DXR stock a 52-week price range ratio of 86.68%

Daxor Corporation currently has a PE ratio of 11.70, a price-to-book (PB) ratio of 2.62, a price-to-sale (PS) ratio of 7.97, a price to cashflow ratio of 26.90, a PEG ratio of 2.32, a ROA of 22.86%, a ROC of -% and a ROE of 25.79%. The company’s profit margin is 90.72%, its EBITDA margin is -%, and its revenue ttm is $6.94 Million , which makes it $1.72 revenue per share.

Of the last four earnings reports from Daxor Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Daxor Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Daxor Corporation is Strong Buy (1), with a target price of $22, which is +60.58% compared to the current price. The earnings rating for Daxor Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Daxor Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Daxor Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 32.08, ATR14 : 0.76, CCI20 : 36.63, Chaikin Money Flow : 0.23, MACD : 0.29, Money Flow Index : 70.45, ROC : 0.07, RSI : 34.63, STOCH (14,3) : 62.50, STOCH RSI : 0.22, UO : 40.93, Williams %R : -37.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Daxor Corporation in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
Summary RatingStrong Buy
1.00
Strong Buy
1.00
-
0.00

Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

CEO: Michael Feldschuh

Telephone: +1 212 330-8500

Address: 350 Fifth Avenue, New York 10118, NY, US

Number of employees: 750

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

57%43%

Bearish Bullish

54%46%

TipRanks News for DXR

Wed, 09 Mar 2022 12:36 GMT Daxor (DXR) Gets a Buy Rating from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits